Resmed (RMD) Stock Forecast & Price Target

Compare

1,092 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RMD Analyst Ratings

Moderate Buy

8 Buy

6 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Resmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$266.00

▲(3.82%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $266.00 with a high forecast of $290.00 and a low forecast of $240.00. The average price target represents a 3.82% change from the last price of $256.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"184":"$184","291":"$291","210.75":"$210.8","237.5":"$237.5","264.25":"$264.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$290.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$266.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$240.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[184,210.75,237.5,264.25,291],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.03,247.56615384615384,251.1023076923077,254.63846153846154,258.1746153846154,261.71076923076924,265.24692307692305,268.7830769230769,272.3192307692308,275.8553846153846,279.39153846153846,282.9276923076923,286.46384615384613,{"y":290,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.03,245.72,247.41,249.1,250.79,252.48,254.17000000000002,255.86,257.55,259.24,260.93,262.62,264.31,{"y":266,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.03,243.72,243.41,243.1,242.79,242.48,242.17,241.86,241.55,241.24,240.93,240.62,240.31,{"y":240,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":187.21,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.49,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$290.00

Average Price Target$266.00

Lowest Price Target$240.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brett FishbinKeyBanc

KeyBanc

$268→$274

Buy

6.94%

Upside

Reiterated

06/17/25

KeyBanc Reaffirms Their Buy Rating on Resmed (RMD)

David BaileyMorgan Stanley

Morgan Stanley

$280→$286

Buy

11.63%

Upside

Reiterated

05/20/25

Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities

Lyanne HarrisonBank of America Securities

Bank of America Securities

$280

Buy

9.29%

Upside

Reiterated

05/20/25

Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109's Appeal

Marcus CurleyUBS

UBS

$285

Buy

11.24%

Upside

Reiterated

05/20/25

UBS reiterates Buy Rating on ResMed (RMD)UBS analyst Marcus Curley reiterated a Buy rating and $285.00 price target on ResMed (NYSE: RMD).

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/20/25

Resmed (RMD) Receives a Hold from Needham

Unknown AnalystJefferies

Not Ranked

Jefferies

―

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on RMD.

Craig Wong-PanRBC Capital

RBC Capital

$247→$255

Hold

-0.47%

Downside

Reiterated

04/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Resmed (NYSE: RMD) and Thermo Fisher (NYSE: TMO)

Suraj KaliaOppenheimer

Oppenheimer

―

Hold

―

Reiterated

04/24/25

Oppenheimer reiterates Perform Rating on ResMed (RMD)Oppenheimer analyst Suraj Kalia reiterated a Perform rating on ResMed (NYSE: RMD).

Adam MaederPiper Sandler

Piper Sandler

$260→$248

Hold

-3.20%

Downside

Reiterated

04/24/25

Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)

Anthony PetroneMizuho Securities

Mizuho Securities

$265→$250

Buy

-2.42%

Downside

Reiterated

04/24/25

ResMed price target lowered to $250 from $265 at MizuhoResMed price target lowered to $250 from $265 at Mizuho

Jonathan BlockStifel Nicolaus

Stifel Nicolaus

$240

Hold

-6.33%

Downside

Reiterated

04/24/25

Stifel Nicolaus Keeps Their Hold Rating on Resmed (RMD)

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/24/25

ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating

David LowJ.P. Morgan

J.P. Morgan

$286→$290

Buy

13.19%

Upside

Reiterated

04/24/25

ResMed (RMD) PT Raised to $290 at JPMorganJPMorgan analyst David Low raised the price target on ResMed (NYSE: RMD) to $290.00 (from $286.00) while maintaining a Overweight rating.

Joseph VruwinkRobert W. Baird

Robert W. Baird

$286→$252

Buy

-1.64%

Downside

Reiterated

04/10/25

ResMed (RMD) PT Lowered to $252 at BairdBaird analyst Joe Vruwink lowered the price target on ResMed (NYSE: RMD) to $252.00 (from $286.00) while maintaining a Outperform rating.

Unknown AnalystCiti

Not Ranked

Citi

―

Buy

―

Upgraded

03/05/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brett FishbinKeyBanc

KeyBanc

$268→$274

Buy

6.94%

Upside

Reiterated

06/17/25

KeyBanc Reaffirms Their Buy Rating on Resmed (RMD)

David BaileyMorgan Stanley

Morgan Stanley

$280→$286

Buy

11.63%

Upside

Reiterated

05/20/25

Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities

Lyanne HarrisonBank of America Securities

Bank of America Securities

$280

Buy

9.29%

Upside

Reiterated

05/20/25

Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109's Appeal

Marcus CurleyUBS

UBS

$285

Buy

11.24%

Upside

Reiterated

05/20/25

UBS reiterates Buy Rating on ResMed (RMD)UBS analyst Marcus Curley reiterated a Buy rating and $285.00 price target on ResMed (NYSE: RMD).

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/20/25

Resmed (RMD) Receives a Hold from Needham

Unknown AnalystJefferies

Not Ranked

Jefferies

―

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on RMD.

Craig Wong-PanRBC Capital

RBC Capital

$247→$255

Hold

-0.47%

Downside

Reiterated

04/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Resmed (NYSE: RMD) and Thermo Fisher (NYSE: TMO)

Suraj KaliaOppenheimer

Oppenheimer

―

Hold

―

Reiterated

04/24/25

Oppenheimer reiterates Perform Rating on ResMed (RMD)Oppenheimer analyst Suraj Kalia reiterated a Perform rating on ResMed (NYSE: RMD).

Adam MaederPiper Sandler

Piper Sandler

$260→$248

Hold

-3.20%

Downside

Reiterated

04/24/25

Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)

Anthony PetroneMizuho Securities

Mizuho Securities

$265→$250

Buy

-2.42%

Downside

Reiterated

04/24/25

ResMed price target lowered to $250 from $265 at MizuhoResMed price target lowered to $250 from $265 at Mizuho

Jonathan BlockStifel Nicolaus

Stifel Nicolaus

$240

Hold

-6.33%

Downside

Reiterated

04/24/25

Stifel Nicolaus Keeps Their Hold Rating on Resmed (RMD)

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/24/25

ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating

David LowJ.P. Morgan

J.P. Morgan

$286→$290

Buy

13.19%

Upside

Reiterated

04/24/25

ResMed (RMD) PT Raised to $290 at JPMorganJPMorgan analyst David Low raised the price target on ResMed (NYSE: RMD) to $290.00 (from $286.00) while maintaining a Overweight rating.

Joseph VruwinkRobert W. Baird

Robert W. Baird

$286→$252

Buy

-1.64%

Downside

Reiterated

04/10/25

ResMed (RMD) PT Lowered to $252 at BairdBaird analyst Joe Vruwink lowered the price target on ResMed (NYSE: RMD) to $252.00 (from $286.00) while maintaining a Outperform rating.

Unknown AnalystCiti

Not Ranked

Citi

―

Buy

―

Upgraded

03/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

1 Month

xxx

Success Rate

12/19 ratings generated profit

Average Return

+4.12%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +4.12% per trade.

3 Months

xxx

Success Rate

14/22 ratings generated profit

Average Return

+5.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +5.35% per trade.

1 Year

Lyanne HarrisonBank of America Securities

Success Rate

18/22 ratings generated profit

Average Return

+14.83%

reiterated a buy rating last month

Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +14.83% per trade.

2 Years

xxx

Success Rate

20/22 ratings generated profit

Average Return

+23.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +23.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating

Jan 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RMD has received 16 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 266.00.

Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.48 with a range of $2.35 to $2.60. The previous quarter’s EPS was $2.37. RMD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.33B with a range of $1.30B to $1.35B. The previous quarter’s sales results were $1.29B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Resmed’s 12-month average price target is 266.00.

What is RMD’s upside potential, based on the analysts’ average price target?

Resmed has 3.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RMD a Buy, Sell or Hold?

Resmed has a consensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.

What is Resmed’s price target?

The average price target for Resmed is 266.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $290.00 ,the lowest forecast is $240.00. The average price target represents 3.82% Increase from the current price of $256.21.

What do analysts say about Resmed?

Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Resmed (RMD) Stock Forecast & Price Target

RMD Analyst Ratings

RMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Resmed

RMD Analyst Recommendation Trends

RMD Financial Forecast

RMD Earnings Forecast

RMD Sales Forecast

RMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts